All Categories

Heart failure medicine recommended for EU approval ‘Novartis’

 Novartis AG’s new heart failure medicine, Entresto, has been recommended for approval in Europe by a review body, the company said on Friday.
The approval by the Committee for Medicinal Products for Human Use puts Entresto on track to be approved for heart failure and reduced ejection fraction (HFrEF) patients across Europe likely by year-end, the company said.
Pending final approval by the European Commission, Entresto will be available for the treatment of adult patients with symptomatic chronic HFrEF, the company said.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker